Patent ID: 8404856

Claim:
A compound, or a pharmaceutically acceptable salt or prodrug thereof, wherein the compound is a compound of Formula III: R 1 is AryA which is phenyl or naphthyl, wherein the phenyl or naphthyl is optionally substituted with from 1 to 3 substituents each of which is independently halogen, CN, NO 2 , C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkenyl substituted with CN, OH, O—C 1-4 alkyl, O—C 1-4 haloalkyl, N(R A )R B , C(O)N(R A )R B , C(O)R A , CO 2 R A , SR A , S(O)R A , SO 2 R A , SO 2 N(R A )R B , or SO 2 N(R A )C(O)R B ; R 2B and R 2C are each independently: (1) H, (2) C 1-4 alkyl, (3) CF 3 , (4) CH 2 CF 3 , (5) CH 2 OH, (6) CH 2 O—C 1-4 alkyl, (7) CH 2 CN, (8) CH 2 N(R A )R B , (9) CH 2 C(O)N(R A )R B , (10) CH 2 C(O)R A , (11) CH 2 CO 2 R A , (12) CH 2 S(O) 2 R A , (13) O—C 1-4 alkyl, (14) OCF 3 , (15) Cl, (16) Br, (17) F, (18) CN, (19) NO 2 , (20) N(R A )R B , (21) C(O)N(R A )R B , (22) C(O)R A , (23) C(O)—C 1-4 fluoroalkyl, (24) C(O)OR A , (25) S(O) 2 R A , (38) cyclopropyl, or (39) O-cyclopropyl; V is H, CH 3 , C(O)CH 3 , C(O)OCH 3 , or S(O) 2 CH 3 ; R F is H, C 1-4 alkyl, Br, Cl, F, or CN; L is a single bond that attaches the ring nitrogen directly to M, CH 2 , or CH(CH 3 ); M is CH 2 or CH(CH 3 ); Z is G 1 or G 2 ; G 1 is: G 2 is: and provided that when Z is G 2 , then L is CH 2 or CH(CH 3 ), and M is CH 2 or CH(CH 3 ); R 4 and R 5 are each independently: (1) H, (2) C 1-4 alkyl, (3) CF 3 , (4) CH 2 CF 3 , (5) CH 2 OH, (6) CH 2 O—C 1-4 alkyl, (7) CH 2 CN, (8) CH 2 N(R A )R B , (9) CH 2 C(O)N(R A )R B , (10) CH 2 C(O)R A , (11) CH 2 CO 2 R A , (12) CH 2 S(O) 2 R A , (13) O—C 1-4 alkyl, (14) OCF 3 , (15) Cl, (16) Br, (17) F, (18) CN, (19) NO 2 , (20) N(R A )R B , (21) C(O)N(R A )R B , (22) C(O)R A , (23) C(O)—C 1-4 fluoroalkyl, (24) C(O)OR A , (25) S(O) 2 R A , (38) cyclopropyl, (39) O-cyclopropyl, (40) OH, or (41) imidazolyl; each T 1 is independently H, C 1-4 alkyl, C(O)R A , C(O)O R A , C(O)N(R A )R B , or S(O) 2 R A ; R6 is: (1) H, (2) C 1-4 alkyl, (3) OH, (4) O—C 1-4 alkyl, (5) NH 2 , (6) N(H)—C 1-4 alkyl, (7) N(—C 1-4 alkyl) 2 , or (8) a saturated heterocyclic ring selected from the group consisting of 1-azetidinyl, 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 1-azepanyl, 4-morpholinyl, and 4-thiomorpholinyl wherein the S in the ring is optionally S(O) or S(O) 2 , wherein the heterocyclic ring is optionally substituted with 1 or 2 substituents each of which is independently C 1-4 alkyl, C(O)—C 1-4 alkyl, C(O)O—C 1-4 alkyl C(O)NH 2 , C(O)NH(—C 1-4 alkyl), C(O)N(—C 1-4 alkyl) 2 , or S(O) 2 -C 1-4 alkyl; R 7 is H or C 1-4 alkyl; each R A is independently H or C 1-4 alkyl; and each R B is independently H or C 1-4 alkyl.